CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD) with inadequate response to at least 2 oral antidepressants.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray ... antagonist of the N-methyl-D-aspartate (NMDA) receptor. Where it differs, however, is ...

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an inadequate response to at least two oral antidepressants, maker Johnson & ...

Esketamine, the S isomer of ketamine ... GM-1020 is a small-molecule orally active antagonist of the N-methyl-d-aspartate (NMDA) receptor that is under development for depression and other ...

NMDA receptors, members of the excitatory ionotropic glutamate receptor family, are essential to these processes. They regulate the strength of synaptic connections, playing a critical role in ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

Esketamine is unique in its mechanism as a non-competitive N-methyl D-aspartate (NMDA) receptor antagonist. Although its mechanism of action is not completely understood, what is known is that the ...

Kelsey Warren [email protected]  609 218 4053 Investor contact: Lauren Johnson [email protected] ...

NMDA receptors in the brain and other areas of ... the scientific and medical communities about the difference between esketamine versus ketamine, and whether esketamine is as effective as regular ...